Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akari Therapeutics PLC (AKTX) vs Palatin Technologies, Inc. (PTN)

Akari Therapeutics PLC and Palatin Technologies, Inc. are both Biotechnology companies. Akari Therapeutics PLC and Palatin Technologies, Inc. are of similar size ($17.6M and $17.5M). Akari Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Palatin Technologies, Inc. trades at 2.4×. Akari Therapeutics PLC has the higher net margin (0.00% vs −47.2%) and the higher return on invested capital (−167.9% vs −942.3%). Across the 14 metrics below, Akari Therapeutics PLC leads on 8 and Palatin Technologies, Inc. on 6.

Valuation

Metric AKTX PTN Biotechnology median
P/E n/m 2.43 7.88
P/S n/m 2.99 11.47
P/B 0.94 3.73 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 2.23 10.73
Earnings yield (265.10%) 41.20% (28.84%)
Free cash flow yield (61.74%) (37.93%) (23.03%)

Profitability

Metric AKTX PTN Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (49.26%) 0.00%
Net margin 0.00% (47.22%) 0.00%
Free cash flow margin 0.00% (113.25%) 0.00%
Return on equity (140.09%) (297.25%) (57.72%)
Return on assets (69.16%) (73.72%) (49.22%)
Return on invested capital (167.93%) (942.30%) 0.00%

Growth

Metric AKTX PTN Biotechnology median
Revenue growth (TTM) — 86.46% 5.64%
EPS growth (last fiscal year) 68.99% 68.15% —
Revenue growth, 5-year CAGR — (40.52%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKTX PTN Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 0.60 5.04 4.73
Net debt to EBITDA 0.27 0.15 0.96

Dividend

Metric AKTX PTN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AKTX PTN Biotechnology median
Market cap 17.61m 17.49m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack